Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyo… Read more
Market Cap & Net Worth: Kezar Life Sciences Inc (KZR)
Kezar Life Sciences Inc (NASDAQ:KZR) has a market capitalization of $49.87 Million ($49.87 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22930 globally and #8056 in its home market, demonstrating a -2.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kezar Life Sciences Inc's stock price $6.81 by its total outstanding shares 7323156 (7.32 Million).
Kezar Life Sciences Inc Market Cap History: 2018 to 2026
Kezar Life Sciences Inc's market capitalization history from 2018 to 2026. Data shows change from $1.73 Billion to $49.87 Million (-34.37% CAGR).
Index Memberships
Kezar Life Sciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #613 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2023 of 3165 |
Weight: Kezar Life Sciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kezar Life Sciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kezar Life Sciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.91x
Kezar Life Sciences Inc's market cap is 9.91 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $69.38 Million | $7.00 Million | -$101.87 Million | 9.91x | N/A |
Competitor Companies of KZR by Market Capitalization
Companies near Kezar Life Sciences Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Kezar Life Sciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Kezar Life Sciences Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Kezar Life Sciences Inc's market cap moved from $1.73 Billion to $ 49.87 Million, with a yearly change of -34.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $49.87 Million | +8.27% |
| 2025 | $46.06 Million | -6.40% |
| 2024 | $49.21 Million | -29.07% |
| 2023 | $69.38 Million | -86.54% |
| 2022 | $515.55 Million | -57.89% |
| 2021 | $1.22 Billion | +220.31% |
| 2020 | $382.27 Million | +30.17% |
| 2019 | $293.66 Million | -83.01% |
| 2018 | $1.73 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Kezar Life Sciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $49.87 Million USD |
| MoneyControl | $49.87 Million USD |
| MarketWatch | $49.87 Million USD |
| marketcap.company | $49.87 Million USD |
| Reuters | $49.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.